E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Critical illness requiring ventilation |
|
E.1.1.1 | Medical condition in easily understood language |
A serious illness which requires the patient to need assistance with breathing |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10077264 |
E.1.2 | Term | Critical illness |
E.1.2 | System Organ Class | 10018065 - General disorders and administration site conditions |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003541 |
E.1.2 | Term | Assisted ventilation |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1) To demonstrate and quantify the test reliability of this novel imaging test. Test reliability is a composite of the following two variables.
a. Precision: Does the new test give the same result when the same lung segment is repeatedly tested. b. Accuracy: Does the new test give different results when lung segments known to be different (for example because of Xray results)?
|
|
E.2.2 | Secondary objectives of the trial |
1) To demonstrate the safety of NAP/FE
2) Additional secondary objectives are designed to assess test validity. They are divided into clinical and biological correlates. The secondary objectives are considered to be exploratory; therefore statistical analyses will not be pre-specified for all comparisons.
a. Clinical: To assess the capability of NAP and FE to predict and correlate with the following outcomes/occurrences within the first 7 calendar days of admission:
i. Oxygenation index ii. PF ratio iii. Ventilator free days (VFDs) iv. Ventilator associated event (VAE) • Occurrence of at least one event per patient • Number of events in studied cohort v. Berlin Criteria assessment for ARDS • Occurrence of at least one event per patient • Number of events in studied cohort • Time (days) to first occurrence • Severity at first occurrence vi. Mean sequential organ failure assessment (SOFA) score vii. Mortality • 7-day • ITU • |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
For all participants: • Participants aged 16 years or over • Participants who are predicted to require intubation for more than two calendar days, with this assessment made by a clinician (Registrar or Consultant in Intensive Care) who is independent of the study team. • Participants who have undergone chest radiological imaging within the preceding 48 hours prior to enrolment. • Participants who can undergo study bronchoscopy within the initial time period (C.D. 0-2) of first intubation in their present hospital admission (as determined by the absence of exclusion criteria for bronchoscopy laid out below).
For BAL subset (up to a total of 10 participants) • Permission given to undertake a BAL by independent attending consultant • CONTROL BAL (n=5) o Absence of pulmonary infiltrates on the aforementioned chest radiological imaging • ABNORMAL BAL (n=5) o Pulmonary infiltrate on chest radiological imaging o Suspicion of community acquired pneumonia or ventilator associated pneumonia as determined by the clinical care team.
|
|
E.4 | Principal exclusion criteria |
For enrolment into the study • Absence of consent from the participant or their personal or professional legal representative • Documented history of allergy to fluorescein • Pregnancy
Prior to each bronchoscopy (as assessed within 24 hours of the start of the procedure) • Investigator not available to perform bronchoscopy with NAP/FE within the pre-specified time • Treatment withdrawal documented to take place within the next 24 hours • Presence of pneumothorax or intercostal chest drain • Refusal by the patient’s attending intensive care consultant
Prior to each study blood sampling • Haemoglobin (Hb) < 6.5 g/dL.
Prior to each BAL • Refusal to permit BAL by the participants attending consultant
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
NAP signal during multiple transbronchial passes of the same segment in the same patient.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
During each NAP/FE bronchoscopy procedure |
|
E.5.2 | Secondary end point(s) |
Completion of at least one NAP/FE examinations in 10 of the 75 recruited participants selected and consented to undergo broncho-alveolar lavage: o 5 with no pulmonary infiltrates on radiological imaging o 5 with at least one pulmonary infiltrate which is suspected to be due to community acquired or ventilator associated pneumonia Safety - assessed by occurrence of adverse reactions. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
End of study and last assessment on day 9 after enrolment (excepting mortality assessment at 90 days) for safety |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit , last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |